News & Events

San Diego, CA - July 30, 2001 - BD Biosciences (BDB) announced today that it has entered into a supply and collaboration agreement with Zyomyx, Inc. Under the terms of this agreement, BDB will make available its growing antibody library to facilitate the development of Zyomyx' high-density protein biochips. Zyomyx will engage BDB to develop, manufacture, and supply antibodies for Zyomyx' research applications.

"This collaboration with Zyomyx strengthens our position as a leading content provider in the field of proteomic research, and builds on our recent efforts to expand the antibody libraries available through BDB," explains Deborah J. Neff, president, BD Biosciences. "We believe that this partnership will leverage Zyomyx' proprietary array technology with our antibody libraries to provide innovative tools to researchers all over the world."

"BD Biosciences is a leading provider of antibody technologies against cellular and intracellular markers in human, mouse, and other species," says Lawrence K. Cohen, Ph.D., chief executive officer, Zyomyx. "Our collaboration with BD Biosciences will greatly expand our antibody resources and enhance our capability to develop superior protein biochips."

BDB, a division of BD (Becton, Dickinson and Company) (NYSE:BDX), provides innovative tools, systems and solutions supporting the life sciences around the world, accelerating the pace of discovery and diagnosis. From genes to proteins to cells, BDB offers integrated, high-value applications in drug discovery and development, flow cytometry systems, immune function monitoring, and functional genomics. With fiscal year 2000 revenues of approximately $550 million, BD Biosciences is comprised of Clontech Laboratories, Discovery Labware, Immunocytometry Systems, Pharmingen and Transduction Laboratories, names that have been known and trusted in the life sciences for years.

BD is a medical technology company that manufactures and sells a broad range of supplies, devices and systems for use by healthcare professionals, medical research institutions, industry and the general public.

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; BD's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in health care or other governmental regulation, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. BD does not intend to update any forward-looking statements.

Zyomyx is a trademark of Zyomyx, Inc. All rights reserved.